Drug Trial Radar · NCT05054140
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
Last checked: Nov 19, 2026Latest source record: Apr 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
450
Planned (sponsor's estimate)
Start
Sep 30, 2021
Primary completion
Jan 7, 2025
Study completion Jan 7, 2025
Sponsor
- Lead sponsor
- Immunic AGIndustry
- Sponsor type
- Industry
- First posted
- Sep 23, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis - CALLIPER
Conditions
- Multiple Sclerosis
Interventions
IMU-838Drug
IMU-838 tablets
Placebo matching IMU-838Drug
Placebo matching IMU-838 tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of IMU-838 versus placeboTime frame: 120 weeks
Locations
73 sites in 12 countries. Site status is shown where the registry gives one.
Dr. Sonia Kalirao
Coral Springs, Florida
Collier Neurologic Specialists
Naples, Florida
Prof. James Scott
Ormond Beach, Florida
Shepherd Center
Atlanta, Georgia
Consultants in Neurology, Ltd.
Northbrook, Illinois
Dr. Daniel Becker
Lutherville, Maryland
Dr. Mirela Cerghet
Detroit, Michigan
University of New Mexico (UNM), MS Specialty Clinic
Albuquerque, New Mexico
MHAT Pulse
Blagoevgrad, Bulgaria
MHAT"Heart and Brain" EAD
Burgas, Bulgaria
Dr. Maya Danovska
Pleven, Bulgaria
Dr. Plamen Bozhinov
Pleven, Bulgaria
UMHAT Pulmed
Plovdiv, Bulgaria
Dr. Rositsa Krasteva
Rousse, Bulgaria
Dr. Nikolay Georgiev
Shumen, Bulgaria
MHAT Shumen
Shumen, Bulgaria
Dr. Ivan Milanov
Sofia, Bulgaria
MHAT Lyulin
Sofia, Bulgaria
Dr. Rosen Ikonomov
Sofia, Bulgaria
Dr. Penko Shotekov
Sofia, Bulgaria
UMHAT Alexandrovska
Sofia, Bulgaria
Dr. Kana Prinova
Sofia, Bulgaria
Dr. Kosta Kostov
Sofia, Bulgaria
MHAT Sveta Sofia
Sofia, Bulgaria
UMHATSM N.I.Pirogov
Sofia, Bulgaria
UMHAT Prof. Stoyan Kirkovich
Stara Zagora, Bulgaria
Dr. Ara Kaprelyan
Varna, Bulgaria
Montreal Neurological Inst.
Montreal, Canada
The Ottawa Hospital Research Institute
Ottawa, Canada
Fakultni nemocnice
Hradec Králové, Czechia
Datamed GmbH
Cologne, Germany
Klinik und Poliklinik für Neurologie, Universitätsklinikum Dresden
Dresden, Germany
Neuro Centrum Science GmbH
Erbach im Odenwald, Germany
Universitätsklinikum Hamburg Eppendorf
Hamburg, Germany
Dr. Stanislav Groppa
Chisinau, Moldova
Dr. Mihail Gavriliuc
Chisinau, Moldova
Dr. Olesea Odainic
Chisinau, Moldova
Dr. Eva Strijibis
Amsterdam, Netherlands
Alrijne ziekenhuis
Leiderdorp, Netherlands
Dr. Ana Doneva Skopje 1000
Skopje, North Macedonia
Showing 40 of 73 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.